Table 13.

Summary of pen-level prevalence of culture and susceptibility (C/S) results at 1DOF and 13DOF associated with pen-level risk of BRD and C/S results at time of BRD treatment.

BRD risk given pen-level C/S prevalence near arrival
Risk factor	Outcome	Significant risk factors for increasing risk*
Pen prevalence at 1DOF	Risk of BRD ≤ 13DOF	None
Pen prevalence at 1DOF	Risk of BRD ≤ 45 DOF	None
Pen prevalence at 13 DOF	Risk of BRD > 13 DOF	None

Associations between C/S results at time of BRD treatment given pen-level C/S prevalence near arrival
Risk factor	Outcome	Significant risk factors for increasing risk**
Pen prevalence at 1DOF	C/S results at BRD treatment ≤13DOF	Any AMR, macrolide, or tetracycline resistance
Pen prevalence at 1DOF	C/S results at BRD treatment ≤45 DOF	Macrolide or tetracycline resistance
Pen prevalence at 13DOF	C/S results at BRD treatment >13DOF	M. haemolytica, any AMR, macrolide, or tetracycline resistance

* Table 10, ** Table 11.